Condition (MeSH)
Myotonia Congenita
ClinicalTrials.gov lists 28 trials for Myotonia Congenita or a narrower condition beneath it. National Institutes of Health Clinical Center (CC) has the most among industry and government lead sponsors, with 1.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
28 of the 28 trials are tagged with Myotonia Congenita itself; the rest are tagged with a narrower condition beneath it.
When did Myotonia Congenita trials start? (15)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 3
- Not applicable
- Observational
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 5 |
| 2024 | 2 |
| 2023 | 1 |
| 2022 | 1 |
| 2021 | 4 |
| 2020 | 1 |
| 2016 | 1 |
| 2015 | 1 |
| 2014 | 2 |
Showing 10 of 15 earlier years.
No forecast is made for this condition: it averages 2.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Myotonia Congenita trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 3 | 3 |
| Not applicable | 9 |
| Observational | 15 |
How many Myotonia Congenita trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Recruiting | 9 |
| Completed | 15 |
| Terminated | 1 |
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Myotonia Congenita trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Institutes of Health Clinical Center (CC) | 1 |
Which drugs are being tested for Myotonia Congenita? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Mexiletine | 1 |
| Ranolazine | 1 |
| Albuterol | 1 |
Interventions as named in the registry (3)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Lamotrigine use | 1 |
| MRI | 1 |
| Salbutamol Only Product in Oral Dose Form | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Myotonia Congenita? (9)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| The antimyotonic effect of lamotrigine in non-dystrophic myotonias: a double-blind randomized study. | Brain : a journal of neurology | 2017 | Yes |
| Sodium channel slow inactivation as a therapeutic target for myotonia congenita. | Annals of neurology | 2015 | Yes |
| Chloride channels in myotonia congenita assessed by velocity recovery cycles. | Muscle & nerve | 2014 | Yes |
| Approach to the diagnosis of congenital myopathies. | Neuromuscular disorders : NMD | 2014 | Yes |
| From mutation to myotonia in sodium channel disorders. | Neuromuscular disorders : NMD | 1997 | Yes |
Showing 5 of 9 publications.
Prevalence (8)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Thomsen and Becker disease | Point prevalence | 1-9 / 1 000 000 | United Kingdom | GB | Unspecified |
| Congenital myotonia | Point prevalence | 1-9 / 100 000 | Worldwide | Not stated | Exact |
| Congenital myotonia | Point prevalence | 1-9 / 100 000 | Worldwide | Not stated | Exact |
| Thomsen and Becker disease | Point prevalence | 1-9 / 1 000 000 | Netherlands | Not stated | Unspecified |
| Thomsen and Becker disease | Point prevalence | 1-9 / 100 000 | Worldwide | Not stated | Unspecified |
Showing 5 of 8 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Congenital myotonia | 206973 | Exact | Orphadata Science knowledge files, Product 1 |
| Congenital myotonia | 206973 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials and sub-conditions in mesh.